Descrizione del progetto
Un istruttore digitale per il trattamento e l’inalazione nelle malattie respiratorie
La BPCO e l’asma sono gravi malattie polmonari potenzialmente letali e inclini all’aggravamento che rappresentano le più comuni malattie respiratorie croniche. Pur non essendo curabili, possono essere trattate con la somministrazione di farmaci nei polmoni attraverso inalatori. Purtroppo, il 90 % dei pazienti usa i propri inalatori in modo errato, il che provoca un insufficiente apporto di farmaci e un trattamento al di sotto dei migliori risultati possibili. L’applicazione KATA, finanziata dall’UE, è un assistente digitale personalizzato, guidato dall’intelligenza artificiale, per aiutare i pazienti affetti da malattie respiratorie a inalare il loro farmaco in modo più efficace. L’applicazione Kata per smartphone mostra la modalità di inalazione corretta fornendo guida e riscontri in tempo reale. L’applicazione, abbinata alle registrazioni dei valori medici, al programma di attività fisica e alle indicazioni contenute, intende rappresentare un istruttore personale completo per le persone affette da malattie respiratorie.
Obiettivo
IIncreasing industrialization in emerging countries, high levels of pollution and smoking is leading to a rise in chronic respiratory diseases (CRDs) worldwide. Even though CRDs are not curable, there are efficient treatments against them, mainly delivering medication into the lungs using inhalers. Unfortunately, 90% of the patients are not using correctly their inhalers, leading to chronic under-use of the prescribed medication and poor management of the disease. VisionHealth, founded in 2017, provides CRD patients with a unique therapy companion to efficiently manage CRDs – the Kata app. With Kata, dynamic training and personalized feedback for optimal use of any commercial inhaler is, for the first time, possible using a combination of advance technology: (1) Machine Vision (MV) using a SIFT algorithm to discern among inhalers and handling, (2) Voice Recognition (VR) recognizing the drug intake and predicting it with RNN architecture, (3) Machine Learning (ML) linking MV and VR inputs and creating models to predict users’patterns, and (4) Augmented Reality (AR) guiding the user in real time based on the ML input. Kata will empower its users to master the usage of their inhaler by Kata’s personalized digital assistance. Kata will ensure high medication compliance in each inhalation to improve patient’s quality of life and functional capacities. Customers of Kata, healthcare insurance companies (HiCs) and pharmaceutical companies, will be able to reduce costs associated with poor patient health outcome and low adherence to medication. Moreover, these companies will be able to redefine their policies moving towards a patient-centered healthcare using the data collected from Kata’s users. VisionHealth aims at stablishing their business strategies and technical roadmap to launch an advance app into the market that will improve CRD patient’s health and, in addition, will provide highly valuable data to optimize HiCs’ and pharmaceutical companies’ activities.
Campo scientifico
- medical and health sciencesclinical medicinepneumologyasthma
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesartificial intelligencecomputer vision
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
80339 MUNCHEN
Germania
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.